REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP lessened its position in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 44.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 105,668 shares of the biotechnology company’s stock after selling 83,431 shares during the period. ExodusPoint Capital Management LP’s holdings in REGENXBIO were worth $817,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in RGNX. GAMMA Investing LLC grew its holdings in REGENXBIO by 273.1% during the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 2,510 shares in the last quarter. FMR LLC lifted its position in shares of REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,656 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of REGENXBIO during the 4th quarter worth approximately $54,000. EntryPoint Capital LLC purchased a new stake in shares of REGENXBIO during the 4th quarter worth approximately $97,000. Finally, Teacher Retirement System of Texas lifted its position in shares of REGENXBIO by 19.9% during the 4th quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company’s stock worth $97,000 after buying an additional 2,088 shares during the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Morgan Stanley boosted their price objective on shares of REGENXBIO from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Friday, March 14th. Raymond James assumed coverage on shares of REGENXBIO in a research report on Friday, February 7th. They set an “outperform” rating and a $27.00 price objective for the company. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, March 7th. Leerink Partners set a $24.00 price objective on shares of REGENXBIO in a research report on Tuesday, March 18th. Finally, HC Wainwright dropped their price objective on shares of REGENXBIO from $36.00 to $34.00 and set a “buy” rating on the stock in a research note on Monday, March 17th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, REGENXBIO presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.78.

REGENXBIO Stock Down 8.5 %

NASDAQ RGNX opened at $5.41 on Friday. REGENXBIO Inc. has a 52-week low of $5.04 and a 52-week high of $19.38. The stock has a market capitalization of $270.97 million, a P/E ratio of -1.08 and a beta of 1.26. The firm has a 50-day moving average price of $7.05 and a 200 day moving average price of $8.32.

REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The company had revenue of $21.21 million during the quarter, compared to analysts’ expectations of $23.70 million. On average, equities research analysts expect that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.